Litfulo (ritlecitinib) / Pfizer - LARVOL DELTA

Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure (EAACI 2026) - No abstract available

Immunology

Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial. (PubMed, EClinicalMedicine) - P2 | "Further studies are required for both molecules and to better understand responder and non-responder populations. Pfizer Inc."

Journal • P2a data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Novel Coronavirus Disease • Oncology • Pain • Respiratory Diseases • Solid Tumor • ICAM3 • JAK3 • TYK2

Infections and Therapy Lapses Predominate as Flare Triggers on Oral JAK Inhibitors for Alopecia Areata: A Retrospective Cohort Study (AAD 2026) - " Of 52 records, 39 patients responded to treatment (baricitinib 19, tofacitinib 18, ritlecitinib 2). Flares are common even among responders, most frequently following infectious exposures or treatment interruptions, often related to insurance issues. Proactive counseling, measures to prevent coverage gaps, and a standardized rescue protocol are recommended."

Retrospective data • Alopecia • Immunology • Infectious Disease • Novel Coronavirus Disease

Discontinuation Patterns of Ritlecitinib in Alopecia Areata: A Real-World Retrospective Chart Review (AAD 2026) - "In this real-world cohort, ritlecitinib demonstrated treatment persistence, without a difference in age between patients actively taking ritlecitinib and those who discontinued due to insufficient response. These findings underscore ritlecitinib as a viable treatment option and the need for improved insurance access to sustain therapy."

Real-world • Real-world evidence • Retrospective data • Review • Alopecia • Immunology

Safety of Janus kinase inhibitors for treatment of alopecia areata (AAD 2026) - "Among the remaining 118 patients, 78 (66.1%), 66 (55.9%), 34 (28.8%), 11 (9.3%), and 4 (3.4%) were treated with baricitinib, tofacitinib, ritlecitinib, upadacitinib, and ruxolitinib, respectively. These results show a low incidence of serious AEs, suggesting that JAK inhibitors are well tolerated for the treatment of AA in real-world settings. Further investigations are needed to establish the long-term safety profiles of JAK inhibitors for the treatment of AA."

Clinical • Acne Vulgaris • Alopecia • Cardiovascular • Genito-urinary Cancer • Herpes Simplex • Herpes Zoster • Immunology • Infectious Disease • Pneumonia • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor • Varicella Zoster

Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials (AAD 2026) - P2b, P3 | "Through 3 years, 44.4% (12/27) of adolescents had SALT score 0 at ≥1 time point (complete scalp hair regrowth). Most cases of complete scalp hair regrowth also showed normal EBA and ELA scores (83.3%), body hair (83.3%), or fingernails (100%) at any occurrence of when SALT score 0 was reached."

Clinical • Alopecia • Immunology

Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program (AAD 2026) - P2b, P3 | "The majority (61.4%, 35/57) did not have a subsequent increase in SALT score at later visits, and most (84.2%, 48/57) remained at SALT score ≤5 at subsequent visits. Most cases of complete scalp hair regrowth also showed normal EBA and ELA scores (78.9%), body hair (71.9%), or fingernails (89.5%) at any occurrence of when SALT score 0 was reached."

Clinical • Alopecia • Immunology

Clinical Characteristics of JAK Inhibitor-Associated Acne: A Retrospective Review (AAD 2026) - " We retrospectively reviewed charts of patients at Mount Sinai Dermatology prescribed oral JAK inhibitors (abrocitinib, upadacitinib, tofacitinib, ritlecitinib, or baricitinib) with a documented diagnosis of acne...The most frequently used acne treatments were topical tretinoin (n=20), clindamycin (n=18), and oral doxycycline (n=18)... As JAK inhibitor prescriptions rise, acne is an increasingly observed dermatologic adverse event. Defining risk profiles and timing may enhance patient counseling, clinical monitoring, and therapeutic decision-making."

Retrospective data • Review • Acne Vulgaris • Immunology

Clinical Utility and Tolerability of Dupilumab and Janus Kinase Inhibitor (JAKi) Combination Therapy in Alopecia Areata Patients (AAD 2026) - "JAKi therapies included tofacitinib, ritlecitinib, and baricitinib. JAKi-dupilumab combination therapy was well tolerated and effective in three AA patients with inadequate JAKi or dupilumab monotherapy response and/or concomitant AD, warranting larger cohort studies."

Clinical • Combination therapy • Allergic Rhinitis • Alopecia • Contact Dermatitis • Dermatitis • Immunology • Infectious Disease • Inflammation • Nephrology • Novel Coronavirus Disease • Ocular Infections • Ophthalmology • Respiratory Diseases

Nasal hair (vibrissae) involvement in patients with alopecia areata universalis: preliminary results showing density modification and response to oral JAK inhibitors (AAD 2026) - " In this single-center, prospective, observational study, 8 adult patients with AAU who started treatment with Baricitinib or Ritlecitinib were evaluated for nasal hair involvement. Preliminary results suggest that AAU patients may have reduced vibrissae density associated with worsened nasal symptoms that improve with oral JAK inhibitors."

Clinical • Alopecia • Immunology • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Real-World Efficacy Data of Oral Ritlecitinib in Severe Alopecia Areata: A Multicentre UK Experience (AAD 2026) - "Factors associated with a positive outcome included male sex (mean SALT reduction 29.8 at three months, 66.1 at six months; females 12.7, 35.1), prior systemic immunosuppressive therapy (76.0, 92.8 vs. 15.0, 38.2 without prior systemic use), and previous diphenylcyclopropenone (DCP) treatment (23.3, 51.8 vs. 20.1, 35.0 without DCP). Our study identified male sex, prior systemic therapy, and eyebrow/eyelash regrowth were associated with favourable response to oral Ritlecitinib for AA. These findings have implications on clinical practice in terms of patient selection and counselling."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Immunology • JAK3

Real-world study in progress: Characterization and clinical outcomes of alopecia areata patients treated with ritlecitinib in a real-world cohort (PRESTO) (AAD 2026) - P | "Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy and safety in patients aged ≥12 years with alopecia areata (AA) in the pivotal ALLEGRO phase 2b/3 study. Secondary outcomes include %CFB in SALT score at Weeks 48, 72, and 96, and the following assessments at Weeks 24, 48, 72 and 96: the proportions of patients reaching SALT scores of ≤10 and ≤20; improvement in Eyebrow Assessment and Eyelash Assessment scores; improvement in beard assessment and nail involvement; Patient-reported satisfaction response; Patient Global Impression of Change response; and changes in patient-reported quality of life using the Alopecia Areata Patient Priority Outcomes scale total score and emotional symptoms and activity limitations subscores. Participant demographics, clinical characteristics, and AA treatment history will also be assessed."

Clinical • Clinical data • Real-world • Real-world evidence • Alopecia • Immunology • JAK3

Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study (AAD 2026) - "Continued treatment may offer further benefits.3,4 Elevated baseline IgE may associate with reduced response, suggesting atopic status's potential role. Limitations include the SALT classification's possible inability to fully capture psychosocial impact and the small sample size, necessitating larger prospective controlled studies."

Clinical • Real-world • Real-world evidence • Alopecia • Dyslipidemia • Hepatocellular Cancer • Immunology • Metabolic Disorders • Solid Tumor • JAK3

Consistent Efficacy of Upadacitinib in Alopecia Areata Subgroups: Adult, Pediatric, Severe Disease, and JAK-Refractory Patients — A Meta-Analysis (AAD 2026) - "Although baricitinib, deuruxolitinib, and ritlecitinib are FDA-approved for severe AA, upadacitinib is increasingly used off-label. Upadacitinib demonstrates statistically significant and consistent efficacy in AA with a favourable safety profile."

Retrospective data • Alopecia • Immunology • Pediatrics

Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review (AAD 2026) - "Tofacitinib was most frequently used (222 cases; mean 10.4 months), followed by deuruxolitinib (53), baricitinib (20), ruxolitinib (19), upadacitinib (8), ritlecitinib (4), abrocitinib (2), and filgotinib (1)... JAKi are promising for AU, with tofacitinib demonstrating the most consistent regrowth. Evidence is limited, and larger trials are needed to confirm efficacy and safety."

Review • Alopecia • CNS Disorders • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Multiple Sclerosis • Varicella Zoster

Navigating Access to JAK Inhibitors for Alopecia Areata: Prescribing Trends, Insurance Denials, and Treatment Delays (AAD 2026) - "Background: Treatment for alopecia areata (AA) has evolved dramatically with FDA approval of three Janus kinase inhibitors (JAKi) for severe AA: baricitinib, ritlecitinib, and deuruxolitinib...Tofacitinib (48.9%), baricitinib (35.6%), and ritlecitinib (13.3%) were the most commonly prescribed agents, largely by dermatologists (94.4%)... Although JAKi prescriptions for AA have risen post-approval, insurance denials and prolonged wait times remain major barriers, even among severe cases. Larger studies are needed to further characterize these disparities and guide strategies to ensure equitable JAKi access."

Reimbursement • US reimbursement • Alopecia • Immunology

Efficacy of Deuruxolitinib and Ivarmacitinib, Two Recently Available Janus Kinase Inhibitors (JAKIs) for Severe Alopecia Areata (AA): A Bayesian Network Meta-Analysis (NMA) and Matching-Adjusted Indirect Comparison (MAIC) (AAD 2026) - "Background: Although baricitinib and ritlecitinib are approved for severe AA in adults, deuruxolitinib and ivarmacitinib only became available in July 2025 in the US and China, respectively. Ivarmacitinib 4 mg and 8 mg QD offers superior efficacy compared to deuruxolitinib 8 mg BID, supporting its potential as a preferred oral JAKI for severe AA."

Retrospective data • Alopecia • Immunology

Comparative Efficacy of JAK Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison (AAD 2026) - "Although baricitinib, ritlecitinib, and deuruxolitinib are FDA-approved for severe AA, head-to-head randomized controlled trials (RCTs) are lacking. Deuruxolitinib 8 mg BID shows the highest short-term efficacy for severe AA. These findings support prioritization of deuruxolitinib in clinical practice."

Retrospective data • Alopecia • Immunology

B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Pfizer | N=24 ➔ 32

Enrollment change • Dermatology • Hidradenitis Suppurativa • Immunology • Pain

B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Pfizer | N=12 ➔ 24

Enrollment change • Dermatology • Hidradenitis Suppurativa • Immunology • Pain

COMBIVIT: Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo (clinicaltrials.gov) - P2 | N=56 | Not yet recruiting | Sponsor: Centre Hospitalier Universitaire de Nice | Trial primary completion date: Oct 2028 ➔ Jan 2029

Trial primary completion date • Dermatology • Immunology • Vitiligo

Baricitinib Plus Ritlecitinib for Alopecia Areata Universalis: A Case Report (AAD 2026) - "Case Presentation: A 22-year-old male with longstanding alopecia areata universalis (AU) (10 years) had insufficient responses to methotrexate, cyclosporine, and oral JAK-inhibitors (JAKi) baricitinib and ritlecitinib. Optimal treatment to date included ritlecitinib 50 mg daily for the past 15 months, monthly intralesional steroid injections to the scalp and eyebrows, oral minoxidil 5 mg daily, and oral prednisone (tapered from a starting dose of 40 mg over 3 weeks) with which he achieved maximum regrowth of SALT 20 with significant gaps in brows (ClinRO 2) and no notable lashes (ClinRO 3)...A rational combination of baricitinib (JAK1/2 inhibition) and ritlecitinib (JAK3/TEC inhibition) may provide additive or synergistic effects in immunomodulation. In a patient who requested frequent intralesional and oral steroids despite JAKi monotherapy, dual JAKi therapy was safe and effective."

Case report • Clinical • Alopecia • Immunology • JAK3

Comparative Efficacy of Ritlecitinib and Baricitinib for the Treatment of Severe Alopecia Areata in Adolescents (AAD 2026) - " Efficacy data were sourced from ALLEGRO Phase 2b/3 and BRAVE-AA-PEDS, with Baricitinib rates interpolated. Both Ritlecitinib and Baricitinib showed a clear dose response for scalp hair and eyebrow regrowth. In adolescents with severe AA, at Week 24, Baricitinib 4 mg led in efficacy, followed by Ritlecitinib 50 mg and Baricitinib 2 mg. Direct comparisons are needed to confirm relative efficacy."

Clinical • Alopecia • CNS Disorders • Depression • Immunology • Mood Disorders

Real-World Safety of JAK Inhibitors in Skin Immune-Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study. (PubMed, Clin Pharmacol Ther) - "Patients newly prescribed JAKis (tofacitinib, upadacitinib, deucravacitinib, baricitinib, abrocitinib, or ritlecitinib) were propensity score-matched (1:1) with those prescribed cIMs (methotrexate or cyclosporine) based on demographics, baseline skin IMIDs, and comorbidities, yielding 17,068 matched patients. Subgroup analyses, including older adults and those with cardiometabolic risk factors, showed no signal of increased risk, with consistent findings across available agent-level and sensitivity analyses. These results suggest that, over 2 years, JAKis are not associated with increased risks of mortality, MACE, venous thromboembolism, or malignancy compared with conventional systemic agents in patients with skin IMIDs."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Oncology • Psoriasis • Rheumatoid Arthritis • Rheumatology • Venous Thromboembolism

Insurance-Driven Switching and Real-World Treatment Outcomes of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study. (PubMed, J Am Acad Dermatol) - No abstract available

HEOR • Journal • Real-world evidence • Reimbursement • Retrospective data • US reimbursement • Alopecia • Immunology